Cargando…

Correction: Chronic lymphocytic leukemia treatment algorithm 2022

Detalles Bibliográficos
Autores principales:	Hampel, Paul J., Parikh, Sameer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772411/ https://www.ncbi.nlm.nih.gov/pubmed/36543762 http://dx.doi.org/10.1038/s41408-022-00775-6

Ejemplares similares

Chronic lymphocytic leukemia treatment algorithm 2022
por: Hampel, Paul J., et al.
Publicado: (2022)

Chronic lymphocytic leukemia treatment algorithm 2018
por: Parikh, Sameer A.
Publicado: (2018)

Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022
por: Bohn, Jan-Paul
Publicado: (2022)

Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?
por: Roessner, Philipp M., et al.
Publicado: (2021)

Correction: Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
por: Shen, Min, et al.
Publicado: (2013)

Correction: potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis
por: Mukherjee, Priyabrata, et al.
Publicado: (2013)

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2021)

Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
por: Morscio, Julie, et al.
Publicado: (2018)

Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
por: Royo, Romina, et al.
Publicado: (2022)

Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
por: Calissano, Carlo, et al.
Publicado: (2022)

Correction to: Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter’s syndrome
Publicado: (2023)

Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia
por: Johnson, Isla M., et al.
Publicado: (2022)

Correction: Lipoprotein Lipase SNPs rs13702 and rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients
Publicado: (2015)

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
Publicado: (2021)

Isolated anemia in patients with large granular lymphocytic leukemia (LGLL)
por: Salama, Youssef, et al.
Publicado: (2022)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia
por: El-Haj, Nura, et al.
Publicado: (2014)

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2021)

Correction: Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2019)

Correction to: Mituru Takanami, 1929–2022
Publicado: (2023)

Correction to: Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation
por: Sander, Birgitta, et al.
Publicado: (2023)

Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Publicado: (2021)

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
por: Mansouri, Larry, et al.
Publicado: (2023)

Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies
por: Kojima, Kensuke, et al.
Publicado: (2020)

Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2020)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Correction to Lancet Oncol 2022; 23: 125–37
Publicado: (2022)

Correction to Lancet Oncol 2022; 23: 270–78
Publicado: (2022)

Correction to Lancet Psychiatry 2022; 9: 190–91
Publicado: (2022)

Correction to Lancet Oncol 2022; 23: 382–92
Publicado: (2022)

Correction to Lancet Oncol 2022; 23: 501–13
Publicado: (2022)

Correction to Lancet Neurol 2022; 21: 329–41
Publicado: (2022)

Correction to Lancet Oncol 2022; 23: 1097–108
Publicado: (2022)

Correction to Lancet Psychiatry 2022; 9: 307–20
Publicado: (2022)

Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
por: Alaggio, Rita, et al.
Publicado: (2023)

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
por: Steegmann, Juan Luis, et al.
Publicado: (2017)

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia
por: Rodrigues, Celso Arrais, et al.
Publicado: (2016)

Correction to Lancet Infect Dis 2022; 22: 284–94
Publicado: (2022)

Correction to Lancet Respir Med 2022; 10: 327–36
Publicado: (2022)

Correction to Lancet Respir Med 2022; 10: 679–88
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p67u7i12dtggvesk59pohcnrkt